Pacific Biosciences of California, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-67.9M | $-76.1M | $8.2M | $19.6M |
| FY2017 | $-67.5M | $-78.0M | $10.4M | $20.4M |
| FY2018 | $-66.4M | $-68.3M | $1.9M | $23.2M |
| FY2019 | $-78.3M | $-81.1M | $2.8M | $16.4M |
| FY2020 | $19.5M | $18.5M | $1.0M | $17.5M |
| FY2021 | $-111.2M | $-117.1M | $5.9M | $73.4M |
| FY2022 | $-263.2M | $-280.0M | $16.8M | $78.6M |
| FY2023 | $-259.2M | $-268.0M | $8.8M | $72.1M |
| FY2024 | $-206.1M | $-212.2M | $6.2M | $71.0M |
| FY2025 | $-111.2M | $-113.9M | $2.7M | $41.7M |